Skip to main content

Table 1 Risk of progression to active TB across IFN-gamma levels (IU/ml) by model

From: Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose-response meta-regression analysis

IFN-gamma levels (IU/ml)

Relative Risk (95% Uncertainty interval)

Primary Analysis

High Quality Studiesa

Received TPT

No TPT

Adults

Children

0.00

REF

REF

REF

REF

REF

REF

0.10

1.18 (1.07 to 1.32)

1.23 (1.09 to 1.39)

1.26 (1.05 to 1.52)

1.16 (1.02 to 1.32)

1.24 (1.10 to 1.39)

1.13 (1.00 to 1.41)

0.20

1.37 (1.15 to 1.63)

1.45 (1.19 to 1.77)

1.50 (1.10 to 2.01)

1.32 (1.05 to 1.64)

1.46 (1.21 to 1.76)

1.26 (1.00 to 1.81)

0.30

1.55 (1.23 to 1.93)

1.67 (1.29 to 2.14)

1.74 (1.16 to 2.50)

1.48 (1.10 to 1.94)

1.69 (1.32 to 2.12)

1.37 (1.01 to 2.19)

0.35

1.64 (1.28 to 2.08)

1.78 (1.34 to 2.32)

1.86 (1.19 to 2.74)

1.56 (1.12 to 2.09)

1.80 (1.37 to 2.30)

1.43 (1.01 to 2.38)

0.40

1.74 (1.32 to 2.24)

1.88 (1.39 to 2.50)

1.98 (1.23 to 2.97)

1.64 (1.15 to 2.25)

1.90 (1.42 to 2.47)

1.49 (1.01 to 2.57)

0.50

1.93 (1.42 to 2.54)

2.10 (1.50 to 2.84)

2.22 (1.30 to 3.43)

1.81 (1.22 to 2.54)

2.11 (1.53 to 2.81)

1.60 (1.01 to 2.95)

0.70

2.31 (1.63 to 3.09)

2.52 (1.71 to 3.53)

2.68 (1.47 to 4.33)

2.15 (1.38 to 3.09)

2.52 (1.75 to 3.45)

1.81 (1.02 to 3.67)

1.00

2.90 (2.02 to 3.88)

3.14 (2.10 to 4.45)

3.37 (1.81 to 5.64)

2.67 (1.68 to 3.93)

3.09 (2.10 to 4.32)

2.13 (1.03 to 4.73)

2.00

4.99 (3.61 to 6.65)

5.08 (3.29 to 7.50)

5.59 (3.01 to 9.41)

4.56 (3.03 to 6.52)

4.70 (3.15 to 6.66)

3.10 (1.06 to 7.67)

3.00

7.16 (5.07 to 9.65)

6.80 (4.27 to 10.67)

7.65 (4.01 to 12.38)

6.54 (4.09 to 9.88)

5.89 (3.93 to 8.25)

3.95 (1.15 to 11.06)

4.00

9.32 (5.85 to 13.06)

8.31 (4.69 to 14.30)

9.53 (4.75 to 15.19)

8.50 (4.62 to 13.49)

6.73 (4.16 to 9.57)

4.72 (1.28 to 14.53)

5.00

11.38 (6.64 to 16.38)

9.63 (4.87 to 18.00)

11.26 (5.52 to 18.08)

10.42 (4.85 to 17.51)

7.33 (4.31 to 10.81)

5.48 (1.45 to 18.14)

6.00

13.31 (7.37 to 19.43)

10.83 (5.17 to 21.46)

12.90 (6.33 to 20.97)

12.28 (5.31 to 21.43)

7.80 (4.50 to 12.19)

6.30 (1.72 to 21.91)

7.00

15.07 (8.63 to 22.07)

11.99 (5.67 to 24.60)

14.54 (7.61 to 23.07)

14.11 (6.38 to 24.60)

8.27 (5.01 to 13.19)

7.23 (2.03 to 25.37)

8.00

16.61 (10.31 to 24.16)

13.13 (6.29 to 27.22)

16.17 (9.37 to 25.01)

15.84 (8.08 to 26.98)

8.79 (5.62 to 14.14)

8.25 (2.46 to 27.55)

10.00

19.00 (13.08 to 26.90)

15.16 (7.38 to 31.92)

19.10 (12.87 to 29.37)

18.74 (11.01 to 30.36)

9.85 (6.20 to 15.17)

10.24 (2.96 to 33.94)

12.00

20.53 (14.13 to 29.62)

16.74 (7.90 to 35.79)

21.35 (14.11 to 32.55)

20.75 (12.04 to 34.15)

10.78 (6.79 to 16.66)

11.90 (3.47 to 39.68)

15.00

21.82 (14.65 to 32.57)

18.18 (8.39 to 40.54)

23.26 (14.95 to 37.08)

22.39 (12.88 to 38.79)

11.75 (7.14 to 18.99)

13.44 (4.03 to 45.99)

20.00

22.31 (15.43 to 33.00)

18.74 (8.69 to 41.61)

23.82 (15.26 to 37.92)

22.94 (13.27 to 39.56)

12.22 (7.43 to 19.48)

14.04 (4.33 to 46.61)

  1. aSensitivity analysis excluding studies with NOS score < 5
  2. NOTE: TPT (TB preventive treatment). In the TPT subgroup analyses, data inputs into the models were stratified by whether studies provided any TPT. The children subgroup analysis included data for individuals below 18 years, while the adult subgroup analysis included data for those 18 years and older